In patients with non-small cell lung cancer (NSCLC), accurate mediastinal staging is relevant to determine treatment options, estimate prognosis, and provide a common language when communicating about patients and enrolling them in clinical trials. For the last 4 decades, several lymph node maps have been used to defi ne the clinical and pathologic lymph node involvement in patients with lung cancer by labeling intrathoracic lymph node regions using either anatomic descriptions (eg, right lower paratracheal) or numerical levels (eg, 4R). Th ese maps include those by Naruke, American Th oracic Society (ATS), and Mountain Dressler-ATS (MD-ATS), a modifi cation of the ATS map. Th e Naruke map had been used by Japanese surgeons and oncologists, whereas the MD-ATS was widely adopted in North America. Th e International Association for the Study of Lung Cancer (IASLC) has proposed a revision of the TNM staging system in which the N descriptors reconcile the discrepancies between the Naruke and the MD-ATS maps. Th e most striking discrepancy between the two systems was that level 7 subcarinal lymph nodes in the MD-ATS map corresponded
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The purpose of this article is to provide an update on evidence-based methods for mediastinal staging in patients with lung cancer. This is a review of the recently published studies and a summary of relevant guidelines addressing the role of CT scan, PET scan, endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA), and mediastinoscopy as pertinent to lung cancer staging and restaging. The focus is on how these diagnostic methods fi t into the best algorithm for patients with chest imaging abnormalities suspected of malignant disease. Several studies, meta-analyses, and systematic reviews specifi cally targeted the role of PET scan, EBUS-TBNA, and mediastinoscopy for detecting mediastinal lymph node involvement in patients suff ering from lung cancer. Based on the recommendations from the currently published guidelines, algorithms of care are proposed for staging and restaging of the mediastinum. to levels 7 and 10 in the Naruke map. Th us, some tumors were staged as N2 (stage IIIA) according to the MD-ATS map, but they were N1 (stage II) by the Naruke map. Data analyses, treatment options, and outcomes therefore were signifi cantly aff ected by the choice of a particular lymph node map. Th is discrepancy illustrates the relevance of having a unifi ed staging system. For mediastinal staging, this is now off ered by the IASLC map.
Relevance and Impact of Adequate Staging
Th e distinct treatment options and prognosis for any given tumor stage make accurate staging the most relevant step in the management of patients with lung cancer. Staging sequence and completeness prior to curativeintent treatment remain suboptimal. In one study, single (CT scan), bimodality (CT scan plus PET scan or CT scan plus invasive), or trimodality (CT scan, PET scan, and invasive) tests were used to assess for mediastinal metastases. Only 30% of patients had bimodality and 5% had trimodality staging, despite the guidelines recommending for bimodality or trimodality strategies, which have a signifi cantly lower risk of death. 1 Th e Institute of Medicine recommends that patient care should be "STEEEP": safe, timely, eff ective, effi cient, equitable, and patient-centric. For effi ciency, access, and timeliness of an initial procedure in the management of patients with suspected lung cancer, concomitant diagnosis and staging is benefi cial because it avoids additional procedures. It is preferable to perform a biopsy at the site that would confer the highest stage (ie, to perform a biopsy of a suspected metastasis or mediastinal lymph node rather than the primary pulmonary lesion). 2 Timely staging is relevant, as negative outcomes result from delaying therapy. Distant metastases may become evident on serial CT scans or PET scans in 3% of untreated patients at 4 weeks and in 13% at 8 weeks.
Complete restaging, therefore, should be considered if therapy is delayed for 4 to 8 weeks aft er the diagnosis. 3 Safety and eff ectiveness can be ensured by adherence to the guidelines, which recommend mediastinal lymph node sampling as the fi rst invasive test in patients with suspected lung cancer and mediastinal lymph node involvement without distant metastases. Guidelineconsistent care with initial mediastinal sampling results in fewer tests and complications. 4 One study compared outcomes of diagnostic strategies in patients with lung cancer with regional spread without distant metastases. 4 If the fi rst invasive test involved mediastinal sampling, patients were classifi ed as guideline consistent; otherwise, they were classifi ed as inconsistent. Only 21% of patients had guideline-consistent diagnostic evaluations, and 44% never had mediastinal sampling. Patients who had guideline-consistent care required fewer tests than patients with guideline-inconsistent care, including thoracotomies and CT scan-guided biopsies, although they had more transbronchial needle aspirations. As a consequence, patients with guideline-consistent care had fewer pneumothoraces, chest tubes, hemorrhages, and respiratory failure events. 4 Th ree quality gaps are in fact identifi ed in the care of patients with lung cancer: failure to sample the mediastinum fi rst, failure to sample the mediastinum at all, and overuse of thoracotomy. Furthermore, out of the seven process of care quality indicators related to the evaluation of patients with lung cancer, four are related to staging alone and include mediastinal sampling prior to curative-intent surgery for stage IB or higher. 5 Performing a safe, timely, efficient, eff ective, and patient-centric staging requires a coordinated eff ort. Guidelines recommend a multidisciplinary lung cancer team involvement early in a patient's care, which coordinates the optimal approach to staging and specimen acquisition to expedite diagnostic and molecular testing. 2, 6, 7 Normal and Pathologic Mediastinum on CT Scan and PET Scan: Implications for Staging
Contrast-enhanced chest and upper abdominal CT scan is recommended as an initial step for all patients with suspected or confi rmed diagnosis of lung cancer suitable for treatment. [7] [8] [9] [10] Th e revised IASLC system is clinician oriented and should be used for staging, 8 as it unifi es previously used systems and defi nes the borders of the mediastinal, hilar, and interlobar lymph nodes based on CT scan landmarks. 11 To further help clinicians in their routine practice, the American College of Chest Physicians proposed that patients with lung cancer be separated into four categories with respect to the radiographic characteristics of the primary tumor and the lymph nodes based on CT scan fi ndings 12 ( Fig 1 ) . For group A, tissue diagnosis suffi ces, as mediastinal involvement is implied. Group B patients need pathologic confi rmation of their lymph nodes prior to curativeintent treatment. Groups C and D involve patients with normal mediastinal nodes on CT scan. In group C, the presence of a central tumor or suspected N1 disease on CT scan or PET scan (hilar, interlobar nodes) makes the risk of mediastinal (N2, 3) nodal involvement high (20%-25%) despite normal-sized mediastinal nodes negative on PET scan; thus, further tissue confi rmation is needed for this group. For group D, invasive staging is currently not routinely recommended prior to thoracotomy but may be warranted to rule out N1 disease for nonsurgical candidates who will undergo stereotactic body radiation therapy (SBRT). Th e European Society of Th oracic Surgeons guidelines also recommend invasive staging in patients with the primary tumor size . 3 cm, based on higher probability of N2 disease, even when the CT and PET scans are negative for mediastinal lymph node involvement. 13 Spanish Society for Pulmonology and Th oracic Surgery (SEPAR) guidelines recommend invasive staging in patients with low metabolic activity in the primary tumors, as in some adenocarcinomas, since these tumors may be associated with occult N2 disease (ie, pathologic involvement with a negative CT scan and PET scan). 8 Th e term "normal mediastinum" by CT scan criteria is used to defi ne the absence of visualized mediastinal lymph nodes or the presence of nonpathologic-size lymph nodes. CT scan criteria have been used to defi ne the probability of malignant involvement of the mediastinal lymph nodes. Th e most widely used criterion is a short-axis lymph node diameter Ն 1 cm on a transverse CT scan. Th ere is no universal agreement on these defi nitions, however, and diff erent organizations use slightly diff erent cutoff values to defi ne discrete suspicious mediastinal lymph nodes. SEPAR defi nes these as nodes whose smallest diameter is . 15 mm on CT scan with contrast, 8 whereas National Institute for Health and Care Excellence defi nes them as lymph nodes between 10 and 20 mm maximum short axis on CT scan. 10 Overall, however, the median sensitivity and specifi city of CT scanning for identifying mediastinal lymph node metastasis are 55% and 81%, respectively ( Table 1 ) . 12 Th erefore, lymph nodes , 1 cm seen on the CT scan or nodes that may not be visualized at all may have metastatic involvement once sampled by surgical or needle-based techniques.
PET scanning has a higher accuracy than CT scan for the evaluation of mediastinal lymph node involvement from lung cancer. Lymph nodes with higher fl uorodeoxyglucose uptake than that of the surrounding normal mediastinal structure are considered as positive. Lymph nodes with equivocally increased fl uorodeoxyglucose uptake to a level similar to that of the surrounding normal mediastinal structure are interpreted as negative. Th is defi nes a "normal mediastinum" by PET scan criteria.
PET scanning also provides information regarding metastatic disease outside the thorax, except for the brain. [7] [8] [9] [10] Guidelines recommend the use of PET scan and PET-CT scan for staging in patients who are potential candidates for radical treatment (clinical stage IA-IIIA). 7, 8, 10 Figure
-Radiographic characteristics of the primary tumor and associated interlobar, hilar, and mediastinal lymph nodes. Th e American College of Chest Physicians defi nes these groups based on CT scan fi ndings; for the purpose of this article, the integrated CT-PET scan fi ndings are illustrated. A, Group A involves patients with mediastinal infi ltration; discrete lymph nodes can no longer be discerned or measured. Diagnosis is necessary, but mediastinal involvement is implied, and thus a mediastinal staging procedure is not indicated. B, Group B involves patients with mediastinal node enlargement, in whom the size of the discrete nodes can be measured. Th ese patients require pathologic confi rmation (ie, invasive staging). C, D, In Group C, the mediastinal lymph nodes are normal, but there is a high risk for occult N2/N3 disease based on the presence of suspected Ndisease (C) or a central tumor (D). Th ese patients also need invasive staging prior to surgery. E, Group D is composed of patients with a peripheral clinical stage I tumor (the mediastinal, hilar, and interlobar nodes are normal on PET-CT scan). Invasive staging prior to surgery is not recommended in this group unless these patients are considered for stereotactic ablative surgery.
PET scan, however, is less sensitive for lymph nodes with diameters between 7 and 10 mm, which in fact, by convention, may be called "normal" on chest CT scan. Mediastinoscopy, endobronchial ultrasound (EBUS), and esophageal ultrasound (EUS)-guided sampling have identifi ed unsuspected mediastinal metastases in patients with normal-sized lymph nodes without increased PET activity (ie, normal mediastinum on CT scan and PET scan). 14 Overall, the sensitivity and specifi city of PET scan for identifying mediastinal metastasis are approximately 77% and 86%, respectively ( Table 2 [15] [16] [17] [18] ) . 12 Th us, tissue sampling is still required to confi rm PET scan-positive fi ndings. False positives are seen in patients with active infection and infl ammation where there is increased glycolysis. Sarcoidosis, anthracosis, infections, and reactive lymph nodes lead to nodes that are positive on PET scan. In cases of recent lymph node sampling, PET scan may be falsely positive ( Fig 2 ) . False-negative PET scans occur when there is impaired blood fl ow (ie, necrosis) and minimal radiotracer can reach the area or in processes with a low metabolic activity (eg, carcinoid, some adenocarcinomas).
Th erefore, PET scanning is not a defi nitive test. Lymph node sampling improves staging accuracy beyond the ability of PET scanning. 12 In the absence of M1 extrathoracic disease, a PET scan showing hypermetabolism in the mediastinal nodes requires confi rmation. 2, [7] [8] [9] [10] 19 If the PET scan is negative, tissue confi rmation is recommended prior to surgery in any of the following circumstances ( Fig 1 ): 1. Discrete mediastinal lymph nodes is seen on CT scan. 7,8,10,13 2. Central tumor, usually in contact with the mediastinum 7, 8, 13 (A central tumor was defi ned as existing within the proximal one-third of the hemithorax, and a peripheral tumor was defi ned as existing outside the proximal one-third of the hemithorax.) 3. Th e tumor has low maximum standard uptake value. 8 4. Th ere is suspicion for N1 disease. 7, 8, 13 5. Tumor size is . 3 cm. 13 Staging the PET-CT Scan Normal Mediastinum Prior to Curative-Intent Th erapy
Curative-Intent Surgery
For patients with peripheral clinical stage I tumors with negative nodal involvement by CT and PET scan ( Fig 1 ) , invasive preoperative evaluation of the mediastinal nodes is not recommended, 7,13 based on the evidence that PET scan has a false-negative rate of only 3% to 6% in this population. 12 One study, for example, evaluated the role of mediastinoscopy and EUS-fi neneedle aspiration (FNA) in patients with no mediastinal nodal disease on PET-CT scan. 20 Th e incidence of unsuspected pathologic N2 (pN2) disease was 2.9% for mediastinoscopy and 3.7% for EUS-FNA. Patients with clinical N1 (cN1) disease suspected on PET-CT scan had a high incidence of unsuspected pN2 disease (17.6% aft er mediastinoscopy and 23.5% aft er EUS-FNA), This element remains to be further studied FNA 5 fi ne-needle aspiration. See Table 1 legend for expansion of other abbreviation. a Capillary force or action refers to the ability of a medium (usually liquid) to fl ow in a narrow space (eg, small-gauge needle) against gravity. The medium is lifted up inside the needle as a result of cohesion and adhesive forces between the medium and the inner aspect of the needle. The height of the medium column inside the needle is inversely proportional to the radius of the needle, suggesting that the smaller the needle gauge, the more specimen is collected through the capillary action. The specimen is collected in the needle by nonsuction fi ne-needle sampling; this results in less nodal trauma and less blood in the smear without compromising specimen cellularity necessary for cytology diagnosis.
and it was concluded that cytohistologic confi rmation is not recommended for cN0, but it is necessary for cN1. Studies demonstrate that preoperative EBUS could upstage patients with small, peripheral tumors and PET-CT scan-negative mediastinum. In these trials, the overall rate of N2 disease that was not detected by PET or PET-CT scan ranged from approximately 5% to 17%. 14,21-24 Th ese higher rates of detected occult N2 disease in the more recent studies may be partially explained by histologic diff erences in the study populations and by the changes in the lymph node map in which the area of lymph node station 7 has been widened, allowing detection of additional diseased N2 nodes 11 ( Fig 3 ) . Future algorithms for staging the normal PET-CT scan mediastinum may also need to take into account biomarkers (eg, carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 125, or cytokeratin 19 fragment), as these may be useful indicators for nodal staging. 25 Th ey may impact the decision to proceed with invasive staging. 25 For instance, if the N2/N3 node is negative by EBUS but the markers are elevated, surgical staging may be warranted. Although it remains to be determined which marker is most suitable for a specifi c histologic subtype, biomarker-driven risk stratifi cation of PET-CT scan-normal mediastinum is promising and needs further investigation.
Stereotactic Body Radiation Therapy
Open surgery is not feasible in 25% to 35% of patients with stage I NSCLC, and external-beam radiation is off ered as a standard treatment. Conventionally fractionated radiotherapy has been the traditional radiation treatment of these patients, but SBRT, also known as stereotactic ablative radiotherapy, is an alternative. SBRT may be more cost eff ective than conventionally fractionated radiotherapy, wedge resection, or lobectomy for marginally operable patients. 26, 27 Regional failures, however, occur in up to 15% of patients treated with SBRT. 28 Th is may be because prior to SBRT, patients with medically inoperable NSCLC generally have limited, noninvasive staging. 29 At a minimum, however, until more data become available, mediastinal interrogation with EBUS should be performed before patients undergo SBRT. Indeed, mediastinal lymph nodes were found to be positive for metastatic disease in 16% of patients who underwent EBUS prior to SBRT and had no previous radiographic evidence of disease. 30 A prospective study is currently testing whether there is a diff erence in accuracy between CT-PET scan and EBUS-transbronchial needle aspiration (TBNA) for mediastinal staging in patients with NSCLC prior to SBRT. 31 
Sampling Techniques and Sequence for Mediastinal Staging
Th e staging technique should be chosen that is most cost effi cient, least invasive, and has the least delay in care. Each center should plan the sequence of tests so the initiation of treatment is not delayed. 8 Communication among the oncologist, practitioner performing the biopsy, and the pathologist is important to ensure that suffi cient tissue is obtained and processed for diagnosis, staging, and genetic alterations. 2, 7, 8 Needle-based techniques currently proven to be accurate for mediastinal staging include EBUS, EUS, and combined EUS/EBUS, with sensitivities of approximately 89%, 89%, and 91%, respectively. Th ese are the tests of fi rst choice to confi rm mediastinal involvement in accessible lymph node stations. If negative, as of this writing, they should be followed by surgical biopsy. 12 Th is recommendation is based on the studies of EBUS vs mediastinoscopy [32] [33] [34] and applies to patients with enlarged mediastinal lymph nodes on CT scan or high uptake on PET scan ( Fig 4 ) . Th e preferred fi rst needle technique is EBUS-TBNA, because its diagnostic yield is comparable to that of mediastinoscopy. [32] [33] [34] In fact, EBUS has several advantages over mediastinoscopy: reduced invasiveness; ease of restaging; ability to routinely reach posterior subcarinal, hilar, and interlobar nodal stations ( Table 1 ) ; and, in some practices, the lack of requirement for general anesthesia. National Institute for Health and Care Excellence guidelines recommend that every cancer network should have at least one center with EBUS and/or EUS and that the local test performance of EBUS and EUS-guided FNA should be the subject of audit. 10 Studies suggest that the combination of EBUS and EUS allows complementary and near-complete access to all mediastinal lymph node stations 12, [33] [34] [35] ( Table 1 ) . Th e sensitivities of surgery, endosonography (EBUS and EUS), and endosonography followed by surgery if the needle technique was negative were 79%, 85%, and 94%, respectively. 34 A better understanding of the published data and recent evidence, however, challenge the value of combined EBUS and EUS. EUS must be followed by EBUS for complete staging. 36 Lymph node stations 8 2, 4, 7, 10, and 11) .
Th e upper and lower borders are based on the revised International Association for the Study of Lung Cancer lymph node map. Station 2R includes nodes extending to the left lateral border of the trachea. Th e upper border is the apex of the right lung and pleural space and, in the midline, the upper border of the manubrium, and the lower border is the intersection of caudal margin of innominate vein with the trachea. Station 2L includes nodes extending to the left of the left lateral border of the trachea. Th e upper border is the apex of the left lung and pleural space and, in the midline, the upper border of the manubrium, and the lower border is the superior border of the aortic arch. Station 4R includes right lower paratracheal nodes and pretracheal nodes extending to the left lateral border of trachea. Th e upper border is the intersection of caudal margin of innominate vein with the trachea, and the lower border is the lower border of azygos vein. Station 7 is the subcarinal nodal station with the upper border composed of the carina of the trachea and the lower border composed of the upper border of the lower lobe bronchus on the left and the lower border of the bronchus intermedius on the right. Station 4L includes nodes to the left of the left lateral border of the trachea, medial to the ligamentum arteriosum. Th e upper border is the upper margin of the aortic arch, and the lower border is the upper rim of the left main pulmonary artery. Station 10R includes nodes immediately adjacent to the right mainstem bronchus and hilar vessels, including the proximal portions of the pulmonary veins and main pulmonary artery. Th e upper border is the lower rim of the azygos vein, and the lower border is the interlobar region between the right upper lobe and bronchus intermedius. Station 10L includes nodes immediately adjacent to the left mainstem bronchus and hilar vessels, including the proximal portions of the pulmonary veins and main pulmonary artery. Th e upper border is the upper rim of the left pulmonary artery, and the lower border is the interlobar region (left upper lobe and left lower lobe). Station 11R superior is composed of the nodes between the right upper lobe bronchus and bronchus intermedius. Station 11R inferior is between the middle and the right lower lobe bronchi. Station 11L is composed of the nodes between the origin of the left upper and lower lobar bronchi. Ao 5 aorta;
PA 5 pulmonary artery.
and 9, the only ones not accessible by EBUS but accessible by EUS ( Table 1 ) , did not contribute to the increased yield of EUS-FNA. 37 In addition, it is extremely rare that stations 8 and 9 are involved without concurrent involvement of upper mediastinal nodes (stations 2, 4, or 7). 38 In one study of 621 patients who underwent staging according to the European Society of Th oracic Surgeons guidelines, only one of 30 patients with unexpected (ie, negative PET-CT scan) pN2 had involvement in the inferior mediastinum (in station 8). Th ese data do not justify routine exploration of the inferior mediastinum prior to thoracotomy 38 and questions the value of routinely performing EUS in addition to EBUS for staging.
Surgical techniques (mediastinoscopy, video-assisted thoracic surgery [VATS] ) are used when the suspicion is high (CT or PET scan-positive hilar or mediastinal nodes) and needle techniques are negative 2,7-10,19 ( Fig 4 ) . SEPAR recommends mediastinoscopy when three needle-based samples fail to provide a cytopathologic diagnosis or normal lymphatic tissue. In most studies, surgical staging consists of a standard videomediastinoscopy performed in the operating room, under general anesthesia, and patients are discharged to home the same day. Th e median sensitivity of standard cervical mediastinoscopy is 78%, and median negative predictive value (NPV) is 91% ( Table 1 ) . 12 Th e false-negative rate at mediastinoscopy is infl uenced by: lymph node accessibility, number of stations sampled (3 or 5), and diligence with which the nodes are dissected or sampled. In this regard, lymphadenectomy and videomediastinoscopy have better results than traditional mediastinoscopy, with a median sensitivity of 94%, 89%, and 78%, respectively. 12 A surgical staging technique, however, may be the fi rst step for patients with left upper lobe (LUL) tumors because of the predilection for involvement of the aortopulmonary window (APW) nodes (station 5). Invasive assessment of the APW nodes should be performed via Chamberlain, VATS, or extended cervical mediastinoscopy (ECM) if other mediastinal stations are found to be uninvolved. 7 Th ese nodes represent the most important group of N2 nodes not accessible by standard cervical mediastinoscopy ( Table 1 ) . ECM can be added to explore the subaortic and the paraaortic nodal stations if videomediastinoscopy is deemed to be negative by macroscopic inspection of the biopsied or removed lymph nodes or by frozen section examination of macroscopically suspicious lymph nodes. If videomediastinoscopy reveals N2 or N3 disease in other stations, ECM for station 5 and 6 is not recommended. 39 With this procedure, a mediastinoscope is inserted through the suprasternal notch and directed lateral to the aortic arch. In a study of 456 patients with LUL cancers, standard mediastinoscopy accompanied by ECM was found to have a median sensitivity of 71% for identifying station 5, 6 nodal involvement, with a median NPV of 91%. 39 VATS has also been used to assess APW lymph nodes, but specifi c results for stations 5 and 6 have not been reported. 12 
EBUS Sampling Techniques and Novel Processor Functions
Most studies on EBUS-TBNA showed a high yield for diagnosis and staging of lung cancer using a sampling technique that involved several (approximately 10-15) needle revolutions inside the node and the use of suction. 14, 32, 34 Th e current understanding of optimal fi neneedle sampling techniques, however, include capillary action and minimal intranodal trauma ( Fig 5 15,40 ) , methods that may increase the purity of the acquired specimens and, thus, their quality, relevant for molecular analysis ( Table 2 ) . [15] [16] [17] [18] Elastography and vascular imaging may be able to further improve the sensitivity in detecting malignant lymph nodes. [41] [42] [43] Th e power/color Doppler mode allows vascular image pattern classifi cations of the lymph nodes, which could predict metastatic lymph node involvement. Elastography is an imaging modality already available on certain EBUS processors, which permits the evaluation of the relative stiff ness of the tissues. It has already been used in EUS studies for diff erentiating benign from malignant disease, and the data in EBUS are emerging. 42, 43 Although in the era of biomarkerdriven lung cancer treatment tissue acquisition is still required, these processor functions may allow for selecting the intranodal region that lacks necrosis or has greatest amount of malignant tissue to further increase diagnostic yield, specimen quality, and quantity. In addition, the presence of certain sonographic characteristics may predict the lack of, or the presence of, malignant involvement. Evidence and clinical experience suggest that the presence of a "central hilar structure" on EBUS predicts a benign diagnosis (granulomatous infl ammation, reactive lymph node), whereas the "coagulation necrosis sign" predicts malignancy 40 ( Fig 5 ) . Research is needed to clarify how image patterns can alter posttest probability in cases of nondiagnostic EBUS specimens. In most trials comparing EBUS with mediastinoscopy for staging NSCLC, stations 2, 4, and 7 were evaluated and sampled by EBUS if they were . 5 mm on the short axis, starting with N3 and ending with N1 nodes. However, contralateral hilar and interlobar (station 10, 11) nodes were not sampled. [32] [33] [34] In one trial of EBUS-TBNA performed in patients with mediastinum negative on PET-CT scan that reports results on stations 10 and 11, none of the patients with confi rmed lymph node involvement on EBUS had disease in a contralateral station 10 or 11. 14 It is unclear, however, whether the contralateral station 10 and 11 were even sampled. Routinely sampling these stations may not be warranted for the following reasons: (1) in surgical staging, operators routinely sample only contralateral mediastinal (stations 2, 4) and not contralateral hilar and interlobar nodes (stations 10, 11); (2) sampling contralateral station 10 and 11 does not impact staging if a contralateral mediastinal (station 2 or 4) nodes are positive (ie, N3 disease is confi rmed by sampling a mediastinal node). If the contralateral mediastinal stations 2, 4 are negative, and EBUS identifi es a contralateral node . 5 mm (as it is oft en the case in station 11L or 11Rs, even when the CT and PET scans are negative), it is unknown whether these nodes should be routinely sampled. Two arguments favor this strategy: (1) the extremely rare possibility of identifying skipping metastasis to the contralateral hilum/interlobar nodes, and (2) the knowledge of hilar and interlobar N3 disease may aff ect the radiation fi eld in stage IIIB. Specifi cally, the dose of radiation and pneumonitis risk are diff erent when these nodes are included in planning. Research is needed to determine the value of this practice.
Should N1 Nodes Be Sampled During Routine EBUS Mediastinal Staging in Surgical Candidates?
Surgical series report that hilar pN1 disease has a worse prognosis than the more peripheral pN1. 44 Intralobar pN1 could behave as pN0, and hilar pN1 could have similar prognosis as single-station pN2. Since it aff ects prognosis, this subdivision of the pN1 group justifi es sampling of N1 nodes preoperatively, 38 which is possible via EBUS. 45 In patients with potentially resectable clinical N0 or N1 NSCLC based on CT and PET scan, EBUS demonstrated a sensitivity, specifi city, diagnostic accuracy, and NPV to accurately diff erentiate between N0 and N1 disease of 76.2%, 100%, 96.6%, and 96.2%, respectively. 45 Th ese fi ndings highlight the importance of exploring hilar nodes preoperatively either by EBUS or surgically for prognosis and potential induction therapy to cN1 disease confi rmed pathologically. 34 Restaging the Mediastinum Induction therapy followed by surgery is an option for treating patients with stage IIIA NSCLC with discrete mediastinal node involvement. 7 Studies demonstrate the benefi t of induction chemotherapy to surgical resection for patients with clinical N2 disease. 46 If this approach is chosen, the role of mediastinal restaging aft er induction therapy remains unclear, but downstaging and complete pathologic response are good prognostic factors. Some authorities suggest that surgery should only be performed in those patients who have a response in the mediastinum to induction therapy. In this regard, both CT and PET imaging for restaging have been shown to be inaccurate. 47 Invasive restaging, therefore, is warranted if restaging is to be performed. Restaging of the ipsilateral N2 nodes by VATS has been done, but this is limited by radiation and sometimes anatomy (ie, 4R station), resulting in a sensitivity of only 67% and NPV of 73%. 48 A repeat mediastinoscopy has a sensitivity of about 70% to 82% but may pose a technical challenge, and in some series the sensitivity was as low as 30%. 12 As a general concept, the less invasive the staging is, the easier the restaging. Because a fi rst-time mediastinoscopy may be the optimal way to accomplish mediastinal restaging, an argument can be made to always use a needle-based technique initially to document N2/3 involvement, as suggested by current guidelines, and to save mediastinoscopy, if needed, for restaging aft er induction therapy ( Fig 6 ) . Two studies, however, show that EBUS has a sensitivity of 64% and 76%, respectively, for
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